Fibromyalgia Biomarkers: What Blood Research Shows

Fibromyalgia biomarkers are measurable biological signals in blood that researchers link to the condition: immune proteins such as cytokines and chemokines, inflammation markers such as C-reactive protein, and, more recently, patterns in DNA and gene activity. Studies show that single markers rarely separate fibromyalgia from other conditions, which is why the field is moving toward combined signatures. The FM1® Test is built on that idea: it uses a blood sample to look for DNA genomic signatures tied to immune system changes in fibromyalgia, chronic pain and fatigue.
This guide explains what has been studied, what the numbers mean, how doctors diagnose fibromyalgia today, and what a signature-based blood test adds for you or your patients.
TL;DR
- Researchers have studied dozens of blood markers in fibromyalgia, mostly immune proteins (IL-6, IL-8, TNF-α) and CRP, and many are shifted compared with healthy people.
- Individual markers also move in other conditions, so researchers increasingly point to panels and multi-marker signatures instead of one number.
- Doctors still diagnose fibromyalgia from symptoms and a physical exam under ACR criteria, plus basic labs to look for other causes of pain.
- The FM1 Test looks for DNA genomic signatures in a blood draw, with results in about a week, and it is covered by Medicare and insurance.
- Positive respondents are offered access to a no-cost clinical trial.
Table of Contents
- What a biomarker is, and why fibromyalgia has been hard to pin down
- The immune markers researchers have studied
- Why one marker is not enough
- Combined signatures: what recent studies report
- Where the research is heading
- How fibromyalgia is diagnosed today
- What the FM1 Test does
- After you have an answer
- Ready to get an answer
- FAQ
- Sources
What a biomarker is, and why fibromyalgia has been hard to pin down
A biomarker is something you can measure that reflects what is happening in the body: a blood sugar level for diabetes, a troponin level for a heart attack. For fibromyalgia, there has been no equivalent for decades. Diagnosis has relied on what patients report and what a clinician finds, not on a lab value. The 2010 ACR criteria use a Widespread Pain Index (how many body areas hurt) and a Symptom Severity scale (fatigue, unrefreshing sleep, cognitive trouble), with symptoms present for at least three months. Reviewers of those criteria note that they depend on patient reports and subjective scoring.
That is the experience behind many people’s frustration: normal routine labs, a long wait, and a feeling of not being believed. A measurable biological signal would change that conversation, which is why biomarker research matters to patients and to the clinicians who treat them.
The immune markers researchers have studied
The most-studied group is cytokines and chemokines, small proteins that immune cells use to signal each other. They help set how sensitive your nerves are to pain.
A meta-analysis of 40 studies (Kumbhare et al., 2021) found that people with fibromyalgia had higher IL-6, IL-8, TNF-α, interferon gamma, C-reactive protein and brain-derived neurotrophic factor than healthy controls, and lower IL-1β. A 2025 review describes the most consistent cytokine profile as raised TNF-α, IL-6, IL-8 and IL-10, alongside the chemokine eotaxin.
The same review describes a two-way loop. Immune signals sensitize pain pathways in the body and in the central nervous system, and those sensitized pathways in turn activate the immune system, producing more cytokines. In the spinal fluid, raised IL-8 fits with activation of glial cells, the immune cells of the brain and spinal cord. For a patient, this is the biological story behind “it is not in my head”: immune signaling and pain processing are connected.
A 2024 review also reports a study of more than 90 inflammation-related proteins in plasma and spinal fluid that found four proteins separating fibromyalgia from controls in both compartments: CXCL5, CXCL6, MCP-2 and LAP TGF-β1.
Plain-language guide to the main markers
| Marker | What it is | What studies report in fibromyalgia |
|---|---|---|
| IL-6, IL-8, TNF-α | Cytokines that signal inflammation and pain sensitivity | Higher than in healthy controls in pooled analyses |
| IL-1β | A cytokine | Lower than in controls in the 2021 meta-analysis |
| CRP | A general inflammation protein made by the liver | Higher in pooled analyses, with a small average difference |
| CXCL5, CXCL6, MCP-2 | Chemokines that direct immune cells | Differed from controls in blood and spinal fluid in one study |
| BDNF | A protein involved in nerve signaling | Higher than in controls in the 2021 meta-analysis |
Why one marker is not enough
This is the key point for anyone reading the research. Many of these markers also change with stress, depression, poor sleep, obesity and other illnesses. The 2021 meta-analysis concluded that the markers were not specific to fibromyalgia and may reflect coexisting conditions. The 2024 review makes the same point about stress and depression.
A July 2026 meta-analysis in BMC Rheumatology pooled 18 observational studies with 1,605 participants. It found high-sensitivity CRP significantly higher in fibromyalgia (SMD 0.34, 95% CI 0.16 to 0.52), while IL-6, IFN-γ and hair cortisol did not differ significantly. The authors attribute the inconsistency to differences in how studies were done and call for standardized, multicenter, longitudinal work.

The useful reading is this: a lone cytokine level is a blunt tool, because it moves for many reasons. A 2023 review argues that, given the variety of fibromyalgia, a panel of markers, including subtype-specific ones, is the more plausible route to a dependable test. A 2026 umbrella review of 49 meta-analyses reaches a similar view, describing multi-protein panels as promising and calling for standardized protocols and multidimensional approaches.
In other words, the research direction is clear: look at patterns, not single numbers. That is the logic behind our test, which reads DNA genomic signatures rather than one protein level.
Combined signatures: what recent studies report
Several research groups have tested pattern-based approaches, and the numbers are worth knowing because they show why signatures matter.
- Cytokine response assays. A study reviewed in The Search for Biomarkers in Fibromyalgia described an assay measuring IL-6, IL-8, MIP-1α and MIP-1β after stimulating immune cells. In 160 fibromyalgia patients, 98 with rheumatoid arthritis, 100 with lupus and 119 controls, it reported 93% sensitivity and 89% specificity for fibromyalgia versus controls.
- Blood spectroscopy. A 2018 study used infrared and Raman light analysis of blood from 50 fibromyalgia patients and patients with rheumatoid arthritis, osteoarthritis and lupus. The spectral patterns sorted every participant into the correct disease group. A 2024 portable-instrument study of 337 people (179 with fibromyalgia) reported 84% accuracy, 83% sensitivity and 85% specificity.
- Multi-omics. A 2025 Spanish study analyzed blood proteins and gut microbes in 199 women with fibromyalgia and 43 controls. A combined model reached a mean AUC of 0.85. AUC is a score where 0.5 is a coin flip and 1.0 is perfect.
Sensitivity is how often a test catches people who have the condition. Specificity is how often it correctly clears people who do not. A useful fibromyalgia test needs both to be high, in the kind of people who actually come to a clinic with widespread pain.
The comparison with single markers is striking. A 2024 Turkish study of 502 patients and 90 controls tested blood-count ratios (SII, SIRI, AISI) as simple markers, and their AUCs came out between 0.584 and 0.618, barely better than chance. Pattern-based methods report far stronger numbers than one routine blood ratio.

Where the research is heading
The 2018 genetics review of fibromyalgia (D’Agnelli and colleagues) pointed to candidate genes and altered DNA methylation patterns in stress-response genes as research leads. Methylation is a chemical tag that changes how active a gene is. The appeal of DNA-level signatures is that they capture how the immune system is regulated, not just a snapshot of one protein on one day.
A September 2026 review in the Journal of Pain Research describes diagnosis as still depending on clinical criteria, with biomarker research ongoing. For you, the practical meaning is that diagnosis remains a clinician’s decision, and a blood result is most useful as objective evidence that supports that decision.
How fibromyalgia is diagnosed today
Under the ACR criteria, a clinician reviews where you hurt, how severe your symptoms are, and how long they have lasted. The 2010 version asks for a widespread pain score of 7 or more with a symptom severity score of 5 or more, or a pain score of 3 to 6 with a severity score of 9 or more, and symptoms for at least three months. It also asks whether another disorder explains the pain.
That last part is why routine labs are usually ordered. Canadian guidance from the Canadian Pain Society and Canadian Rheumatology Association recommends simple tests such as ESR and CRP to exclude conditions like hypothyroidism, anemia or inflammatory disease. Those tests rule other problems in or out. They do not show fibromyalgia itself.
If you are working out where you stand, our guides on how doctors diagnose fibromyalgia and the key diagnostic steps walk through the process, and a checklist of common early symptoms can help you prepare for the appointment.
What the FM1 Test does
The FM1 Test is a blood test that uses DNA science to identify immune system changes related to fibromyalgia, chronic pain and fatigue. It identifies specific DNA genomic signatures in positive patients, and we developed it so that a result is objective evidence you can bring to your care team, not another opinion.
What that means in practice:
- A simple blood draw. You give a sample at a local facility. No tender point exam or questionnaire is needed to run the test.
- Results within about a week. You are not left waiting for months.
- Insurance and Medicare coverage. The test is Medicare- and insurance-covered, so cost need not be the barrier.
- A path forward if positive. Positive respondents are offered access to a no-cost clinical trial.
For clinicians, the same result gives a documented, objective data point to sit beside the clinical assessment when a patient presents with chronic pain and fatigue. Our research page explains the science behind the test, and our guide to fibromyalgia testing and results shows how to read what comes back.
After you have an answer
Objective evidence can change what comes next: conversations with insurers, employers and family, and treatment planning with your clinician. Treatment for fibromyalgia is individual, and some patients explore options their state allows, such as medical marijuana for fibromyalgia where state rules permit it. Discuss any new treatment, and any change to your current medicines, with your own doctor first.
Our perspective
For years, patients have told us the hardest part was not the pain itself but being doubted. Normal routine labs were read as “nothing wrong,” and the condition was treated as a matter of opinion.
Our view is that the research points one way. Fibromyalgia involves real immune system changes, and single protein levels are too blunt to capture them, because they shift with stress, sleep and other illnesses. A signature in DNA that is found in positive patients is a more meaningful kind of evidence, and that is the approach we built the FM1 Test around.
We believe a person with chronic pain and fatigue deserves a quick blood draw, a result within about a week, insurance coverage, and, if positive, access to a clinical trial at no cost. Evidence that validates what you feel should be part of care, not an obstacle to it.
the author
Ready to get an answer
If you have widespread pain and fatigue and want objective evidence, the FM1 Test needs only a blood draw at a local facility, and results come back within about a week. It is Medicare- and insurance-covered, and positive respondents can join a no-cost clinical trial. You can start your FM1 Test here, or read the FM1 Test FAQ first.

FAQ
Is there a blood test for fibromyalgia?
Yes. The FM1 Test is a blood test that uses DNA science to identify immune system changes related to fibromyalgia, chronic pain and fatigue. It needs a simple blood draw and returns results within about a week. A clinician still places the result alongside your symptoms and history.
Which immune markers are linked to fibromyalgia?
Studies most often report higher IL-6, IL-8, TNF-α and CRP, and altered chemokines such as CXCL5 and eotaxin. Because these proteins also change with stress and other illnesses, researchers favor combined panels and signatures over any single one.
Do I need to pay out of pocket for the FM1 Test?
The test is Medicare- and insurance-covered. You can start the process on our get-started page, and our FAQ covers coverage questions. The test itself has no published price on our site.
What happens if my result is positive?
Positive respondents are offered access to a no-cost clinical trial. The result is also objective evidence you can share with your doctor to guide your treatment plan.
Can routine blood work show fibromyalgia?
Routine labs such as CBC, ESR, CRP and thyroid tests are typically used to look for other causes of pain, not to identify fibromyalgia. That is why a test built on DNA signatures is a different kind of evidence.
Sources
- Potential role of blood biomarkers in patients with fibromyalgia (2021)
- A Review of Etiological Biomarkers for Fibromyalgia (2024)
- Neuroinflammatory and Immunological Aspects of Fibromyalgia (2025)
- Inflammatory biomarker alterations in patients with fibromyalgia (2026)
- Pain Biomarkers in Fibromyalgia Syndrome (2023)
- Neurophysiological, Radiological, and Molecular Biomarkers (2026)
- The Search for Biomarkers in Fibromyalgia
- Metabolic fingerprinting for diagnosis of fibromyalgia (2018)
- Portable Mid-Infrared Spectroscopy for fibromyalgia (2024)
- Fibromyalgia diagnosis from a multi-omics approach (2025)
- Value of Diverse Hematological Markers in Fibromyalgia (2024)
- Fibromyalgia: Genetics and epigenetics insights (2018)
- Evolving Concepts in the Diagnosis and Management of Fibromyalgia (2026)
- Diagnostic Criteria for Fibromyalgia: Critical Review (2020)
- Canadian Pain Society and Canadian Rheumatology Association recommendations (2013)